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ABSTRACT
PURIFICATION AND CHARACTERIZATION OF THE PROSTATE 
CANCER-ASSOCIATED ANTIGEN: 7E11-C5
Qi Feng
Eastern Virginia Medical School 
and
Old Dominion University 
August, 1991 
Director: George L. Wright, Jr., Ph.D.
A murine monoclonal antibody (MAb), designated 7E11-C5, 
described by Horoszewicz et al. (Anticancer Res 7:927-936, 
1987), recognizes a prostate organ-specific antigen. This 
MAb was generated against an established human prostate 
adenocarcinoma cell line, LNCaP. i:L1ln-labeled 7E11-C5 MAb 
has been shown to localize specifically in LNCaP tumors 
grown in nude mice (Lopes et al-, Cancer Res 50:6423-6429. 
1990). The objectives of the present study were to further 
determine the specificity of the target 7E11-C5 antigen, and 
to purify and biochemically characterize the antigen.
Under reducing conditions, the 7E11-C5 antigen 
exhibited a major 100-Kd and a minor 70-Kd band, suggesting 
that the antigen consisted of two peptide chains. These two 
bands were detected in tissue extracts of LNCaP xenografts,
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benign prostatic hyperplasia (BPH) and prostate carcinomas. 
Similar bands were also detected in pooled normal seminal 
plasma. The bands were not identified in any of the non­
prostate tissue extracts tested. Competitive binding 
experiments showed that antibodies to other prostate- 
associated antigens were unable to block the binding of 
7E11-C5 MAb to its target antigen. The molecular weight 
comparison by Western blot demonstrated that there was no 
similarity between the 7E11-C5 antigen and three major 
prostate-associated markers: prostatic acid phosphatase 
(PAP), prostate specific antigen (PSA) and prostate 
secretory protein (PSP). These results together strongly 
indicated that the 7E11-C5 antigen was distinct from other 
known major prostate antigens.
The 7E11-C5 antigen was purified 400-fold from LNCaP 
xenograft tissue homogenate by immunoaffinity chromatography 
with an estimated antigen recovery of 64%. High pressure 
liquid chromatography (HPLC) molecular exclusion column was 
used to further purify the antigen and results showed that 
the molecular weight of the 7E11-C5 antigen, under native 
conditions, was about 500-Kd. Biochemical characterization 
of the 7E11-C5 antigen showed that the antigen was sensitive 
to both periodate oxidation and protease treatment, thus 
indicating that the antigen was a glycoprotein and that both 
carbohydrate and peptide were required for antigenicity.
The antigen was found to be sensitive to pH 2.0, while
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remaining unaffected after treatment with NaOH (pH 11.0), 
sodium dodecyl sulfate (SDS) or 2-mercaptoethanol. 
Glycosidase treatment and lectin competitive binding 
experiments suggested that the carbohydrates involved in the 
antigenic determinant were galactose and N-acetyl-D- 
galactosamine, although carbohydrate competitive binding 
experiments showed that free carbohydrates or carbohydrate 
conjugates were unable to block the antigen-binding site of 
the 7E11-C5 MAb. The 7E11-C5 antigen was not demonstrable 
in thin-layer chromatography (TLC) immunoblot analysis of 
glycolipid extracts of LNCaP tissue.
Western blot analyses of 48 serum samples from age- 
matched normal males, BPH patients and prostate cancer 
patients (stages A, B, c and D) failed to clearly show the 
presence of the 7E11-C5 antigen in the serum samples. 
Likewise, the 7E11-C5 antigen was not detected in these sera 
using a competitive binding inhibition assay. These results 
suggest that the antigen is either not shed into the 
circulation or that the antigen is either masked by serum 
inhibitors or disassociated into fragments not recognized by 
the 7E11-C5 MAb.
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A. REVIEW OF THE LITERATURE
Carcinoma of the prostate (CaP) is the most common male 
malignancy in the United States. Approximately one out of 
eleven men will develop CaP at some time during their life 
time, and the incidence of this disease is steadily 
increasing. Preceded only by lung cancer, CaP ranks as the 
second leading cause of death by cancer among the U.S. male 
population. By the end of 1991, it has been estimated that 
over 122,000 newly diagnosed cases of CaP and more than 
32,000 deaths from this disease will be reported in the 
United States (1, 2).
The CaP patient 5-year survival rate varies with the 
clinical stage of CaP when diagnosed. The survival rate is 
85% for stage A (microscopic), 77% for stage B 
(macroscopic), 65% for stage C (macroscopic and 
extracapsular) and only 29% for stage D (metastatic).
Because localized CaP rarely causes symptoms, metastases 
have already occurred in the majority of cases when first 
diagnosed. Therefore, one of the major problems with 
diagnosis of CaP is that there is no reliable procedure that
R eproduced with perm ission of the copyright owner. Further reproduction prohibited without perm ission.
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can detect early localized disease; a disease which is 
curable with current treatments (3, 4).
One approach to aid in early diagnosis and in 
monitoring the effectiveness of therapy has been the search 
for specific prostate tumor markers. There have been a 
number of studies in which prostate organ-specific markers, 
although not tumor-specific, have demonstrated their 
usefulness for these purposes (5-7). Two such markers, 
prostatic acid phosphatase (PAP) and prostate specific 
antigen (PSA), have become available for clinical use. 
Currently, testing patient serum PAP and PSA levels, 
especially PSA, is utilized both as part, of the clinical 
routine follow-up studies or as a regular guide to 
therapeutic decisions (8, 9).
Since 1938, when the association of elevated serum acid 
phosphatase and advanced-stage CaP was first described by 
Gutman et al. (10), serum PAP measurements have proven 
useful, in some instance, in both the diagnosis of CaP and 
in determining response to therapy. PAP is a monoester 
phosphohydrolase present in large quantities as an exocrine 
secretion of the prostate. However, it has been shown that 
although serum PAP levels become elevated with extracapsular 
growth of CaP in 24-71% of patients, in most patients with 
early disease the serum PAP concentration is within the 
normal range, thereby precluding use of this marker for 
screening high-risk individuals. While PAP levels have
R eproduced with perm ission of the copyright owner. Further reproduction prohibited without perm ission.
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limited application as an early screening measure, these 
values appear more useful in determining response to 
therapies (11, 12).
Prostate specific antigen (PSA) was identified in 1979 
and was shown to be produced exclusively by epithelial cells 
of the prostate. PSA antigen has been purified and found to 
have a molecular weight of 34-Kd; also it has been shown to 
consist of a single peptide chain containing about 7% 
carbohydrates (13-15). Serum PSA levels in both benign 
prostatic hyperplasia (BPH) and in CaP patients have been 
shown to be significantly elevated as compared with those in 
normal males or males with non-prostate cancer. Although no 
quantitative difference in serum PSA levels has been found 
between BPH patients and patients with CaP stage A and stage 
B, patients with stage C or stage D exhibited significantly 
elevated PSA levels. Serum PSA values in CaP patients were 
found to be valuable in predicting survival time, monitoring 
clinical course and early recurrence of CaP. High PSA 
levels in Cap patients are correlated with poor prognosis 
and, in post-operative monitoring, strongly suggest disease 
recurrence. Compared with PAP, PSA appears to be more 
specific and valuable in the diagnosis and prognosis of CaP 
(16-21).
One report suggests that the simultaneous measurement 
of both PAP and PSA in serum can be of added value in 
diagnosis of CaP (22). However, even in this study, only
R eproduced with perm ission of the copyright owner. Further reproduction prohibited without perm ission.
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58% of the CaP patients with stage A and B disease had 
elevated levels of either or both markers, while 10% of the 
BPH patients had positive serum levels for these markers.
In summary, PAP and PSA are prostate organ-specific antigens 
and the assays developed to detect PAP or PSA have limited 
use in early diagnosis since they can not differentiate 
early CaP from BPH (23).
The analysis of human prostatic fluid proteins has 
shown that another abundant 16-Kd protein, prostate 
secretory protein (PSP), is present in addition to PAP and 
PSA (24-28). This 94-residue peptide has been estimated to 
represent at least 20% of the proteins in normal prostate 
fluid. This protein has been detected in prostate tissue as 
well as in the serum and urine from CaP patients, suggesting 
that this protein might be a useful marker for the diagnosis 
and prognosis of CaP (29-31).
In addition to the three prostate tumor-associated 
markers described above, many others have been identified by 
various investigators. Ware et al. (32) described a 
monoclonal antibody (MAb), alpha Pro3, produced against the 
CaP cell line PC3. This MAb reacted with normal prostate, 
BPH and tumors of other organs as well as CaP. Webb et al. 
(33) generated another MAb, alpha Pro5, against a different 
epitope of the alpha Pro3 antigen. In another study,
Frankel et al. (34) using BPH tissue as an immunogen, 
generated a group of prostate-organ specific MAbs. Starling
R eproduced with perm ission of the copyright owner. Further reproduction prohibited without perm ission.
5
et al. (35) generated a MAb, D83.21, by using the CaP cell 
line DU145 as an immunogen. The MAb displayed preferential 
binding to prostate and bladder cancer cell lines and 
tissues, and the D83.21 antigen was characterized as a 
membrane glycoprotein with 28-60 Kd subunits. Another MAb 
described by the same group, designated Turp-27 (36, 37), is 
reactive to a prostate-associated antigen, but also cross 
reacts with central nervous system tissues and peripheral 
nerves. Both Raynor et al. (38) and Carroll efc al. (39) 
have used the CaP cell line PC-3 to generate murine MAbs. 
However, the MAbs reacted with normal prostate, BPH, and 
other cancer cell lines as well as CaP. Bazinet et al* (40) 
reported two MAbs that recognized the same 58-Kd protein 
selectively expressed by CaP epithelial cells but not by 
benign prostate tissue or other normal tissues. Recently, 
Kim et al. (41) described MAb PR92, which is reactive with 
CaP, breast and lung cancer cell lines, but not with normal 
and other cancer cell lines. Another MAb generated in our 
laboratory (42), designated PD-41, was found to react to 60% 
of CaP by immunohistological staining, and to bind minimally 
to normal prostate and BPH tissues. The PD-41 target 
antigen appears to be a mucin-like glycoprotein. Table I 
summarizes the prostate-associated markers discussed above, 
including the 7E11-C5 antigen which is the subject of the 
present study.
A murine MAb, 7E11-C5 (IgGl, k), was described by
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TABLE I
Summary of Prostate-Associated Markers
Marker nature MW (Kd) specificity Ref.
PAP gpa 45-50b organ 11, 12
PSA gp 34 organ 13-16
PSP gp 16 organ? 24-27
Turp-27 gp 35-310 organ 36, 37
KR-P8 gp 48-75 organ 38
alpha Pro3 gp 54 organ? 32
alpha Pro5 gp 54 organ? 33
F77-129 o• organ? 39
D83.21 gp 28-60 organ? 35
P25.48 gp 58 CaP? 40
P25.91 gp 58 CaP? 40
PR92 gp 44 CaP? 41
PD-41 gp 90-400 CaP? 42
7E11-C5 gp 70, 100 organ 43, 46
a glycoprotein.
13 All molecular weights were determined under reducing 
conditions.
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Horoszewicz et al. in 1987 (43). This MAb was generated 
against an established human prostate adenocarcinoma cell 
line, LNCaP (44, 45) and is reactive with an insoluble, 
cytoplasmic fraction of the LNCaP cells. 111In-labeled 
7E11-C5 MAb was recently shown to specifically localize in 
LNCaP tumors grown in nude mice (46). The MAb recognizes a 
prostate organ-specific antigen. The specificity of 7E11-C5 
was observed to be restricted to human prostatic epithelial 
cells, including normal prostate, BPH, and CaP. Except for 
LNCaP, none of the 32 lines of human normal or non-prostate 
neoplasms reacted with MAb 7E11-C5. In a survey of frozen 
sections from 175 human specimens, it was reported that 
positive immunoperoxidase staining was limited to the 
epithelium in all 11 specimens of localized and metastatic 
CaP, 7 BPH and 7 normal prostates. None of the 26 various 
non-prostatic tumors nor 120 out of 122 specimens from 28 
different normal organs were reactive. Using a crude 
competitive binding enzyme linked imraunoabsorbent assay 
(ELISA), Horoszewicz et al. reported the presence of 
circulating 7E11-C5 antigen in 20 out of 43 sera from CaP 
patients. None of 30 normal blood donor sera nor 7 BPH sera 
were positive (43). The ELISA results suggested that the 
antigen was shed in sera of advanced-stage CaP patients (43, 
46). If these results, particularly the serum data, can be 
confirmed with a refined immunoassay, this antigen/antibody 
system might have potential usefulness for diagnosis or 
prognosis of CaP.
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B. FOCUS OF THE PRESENT INVESTIGATION
Although the preliminary ELISA results suggest the 
7E11-C5 antigen could be detected in the serum samples of 
advanced-stage CaP patients, no further reports from the 
same laboratory have been published and their experiments 
have not been confirmed independently. Therefore, the 
sensitivity, specificity and reproducibility of these 
results remain uncertain. The biological function of the 
antigen, the nature of the antigen and the relation of this 
antigen to the other prostate-associated antigens also 
remain unknown. The objectives of this study are:
1. To purify the 7E11-C5 antigen using LNCaP xenograft 
tissues as the antigen source. Unlike the other prostate 
proteins, this antigen is an insoluble cytoplasmic molecule, 
therefore, before chromatography procedures can begin, the 
antigen must first be converted into a soluble form by 
detergents. Various approaches including several 
chromatography procedures, such as molecular exclusion, ion 
exchange, immunoaffinity and high pressure liquid 
chromatography (HPLC), would be applied to purify the 
antigen and a solid-phase radioimmunoassay used to determine 
activity of the antigen.
2. To understand the nature of the antigen. The 
purified antigen would be used to immunologically and
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biochemically characterize the antigen. In general, the 
naturally occurring antigens are proteins or carbohydrates, 
and carbohydrates may be present as part of the antigen in 
the form of a glycoprotein or glycolipid. Protein antigens 
are likely to be sensitive to protease treatments, while 
carbohydrate antigens are likely to be sensitive to 
periodate oxidation treatment which destroys carbohydrate 
residues. Carbohydrate components can be further identified 
using enzymatic deglycosylation and lectin competitive 
binding experiments.
3. To evaluate the potential usefulness of the 7E11-C5 
antigen/antibody system as an adjunct in diagnosis or 
prognosis of CaP. First, serum samples from age-matched 
normal males, BPH and CaP patients (stages A, B, C and D) 
would be evaluated for presence of the 7E11-C5 antigen by 
Western blot, in order to verify the previous report that 
the antigen was shed in the sera of advanced-stage CaP 
patients. Secondly, an immunoassay would be developed to 
detect the antigen in the serum samples. The results from ’ 
7E11-C5 serum assay would be compared with results from 
serum PSA (currently, the most commonly used CaP marker in 
clinic application) in order to determine whether the 7E11- 
C5 antigen level in the serum would provide any additional 
diagnostic or prognostic information for CaP.





1. Tumor tissue and antibodies: The LNCaP nude mouse
xenograft tissues (stored in RPMI-1640 medium and kept in 
-20*c) and the 7E11-C5 MAb (IgGl, k), purified by Protein-A 
chromatography from mouse ascites fluid, were provided by 
CYTOGEN Corporation (Princeton, NJ). Several other murine 
MAbs which were specific to the different prostate- 
associated markers, including anti-PAP (IgG2a), anti-PSA 
(IgGl), anti-PSP (IgGl), Turp-27 (IgG3), PD-41 (IgGl) and 
Leu-7 (IgM), were obtained from the Department of 
Microbiology and Immunology, Eastern Virginia Medical School 
(EVMS). Antibody concentrations were determined using a 
single radial immunodiffusion system (TAGO, Burlingame, CA). 
Normal mouse IgGl, IgG2a, IgG3 and IgM (Bionetics, 
Charleston, SC) were used as controls. Affinity purified 
rabbit anti-mouse IgG (H+L) polyclonal antibodies (Jackson, 
West Grove, PA) were labeled with an<j usea as the
secondary antibody in radioimmunoassay.
2. Chromatography columns, chemicals, enzymes, lectins, 
carbohydrates, organic solvents and radio-isotopes:
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a. Columns: Molecular exclusion, ion exchange, 
immunoaffinity and high pressure liquid chromatography 
(HPLC) columns, including Sephadex G-100, Sephadex G-200, 
Sephacryl S-300, DEAE-Sepharose CL-6B (Pharmacia,
Piscataway, NJ), ImmunoPure Ag/Ab Immobilization Kit #1 
(Pierce, Rockford, IL) and HPLC molecular exclusion column 
(Bio-Sil Sec-250, BioRad, Richmond, CA), were used for 
purification of the 7E11-C5 antigen .
b. Chemicals: Detergents, Nonidet P-40 (NP-40), 3-[(3- 
cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS, 
Sigma, St. Louis, MO) and Octyl-beta-glucoside (Glucoside, 
Boehringer Mannheim, West Germany) were used to solubilize 
the LNCaP tissue extracts. Chemicals, including periodate 
(NaI04, Mallinckrodt, Paris, KY) , sodium dodecyl sulfate 
(SDS) and 2-mercaptoethanol (BioRad), were used to 
characterize the antigen. Chloramine T (Eastman Kodak, 
Rochester, NY), sodium metabisulfite and sodium iodide 
(Mallinckrodt) were used for the antibody iodination.
c. Enzymes: Enzymes, including trypsin type III,
alpha-chymotrypsin, protease type XIV, protease type XXI, 
protease type XXVI, neuraminidase, beta-galactosidase, 
chondroitinase ABC, Endo-beta-N-acetyl-glucosaminidase F 
(Endo F), alpha-L-fucosidase (Sigma), O-glycanase and N- 
glycanase (Genzyme, Boston, MA) were used to characterize 
the antigen.
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d. Lectins: Lectins (E. Y., San Mateo, CA) were used 
to determine the carbohydrate specificity of the antigen, 
including Concanavalia ensiformis (Con A), Griffonia 
simplicifolia II (GS II), Triticum vulgaris (WGA), Dolichos 
biflorus (DBA), Glycine max (SBA), Arachis hvoogaea (PNA), 
Maclura pomifera (MPA), Ulex europaeus I  (UEA I), Limulus 
polvphemus (LPA) and Phaseolus vulgaris (PHA).
e. Carbohydrates and carbohydrate conjugates: 
Carbohydrates and carbohydrate conjugates, including 
melibiose, lactose, L-fucose, D-mannose, N-acetyl-D- 
galactosamine (galNAc), N-acetylglusosamine (glcNAc, E. Y.), 
D-glucose (Mallinckrodt), D-galactose, D-raffinose, 
stachyose, 2-acetamido-2-deoxy-3-0-beta-D-galactopyranosyl- 
D-galactopyranose and N-acetyllactosamine (Sigma) were used 
to characterize the antigen.
f. Organic solvents: Organic solvents used to
characterize the antigen included chloroform, aqueous 
phenol, formic acid, pyridine (Fisher, Fair Lawn, NJ), 
acetic acid (Mallinckrodt), formamide (BRL, Gaithersburg,
MD), dimethylformamide, n-butanol (Sigma), and methanol 
(Quantum, Tuscola, IL).
g. Radio-isotopes: Sodium-125I (Na-125I, ICN, Irvine,
CA), specific activity 40 mCi/ml, was used for antibody 
iodination and 35S-methionine (Amersham, Arlington Heights,
R eproduced with perm ission of the copyright owner. Further reproduction prohibited without perm ission.
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IL), specific activity 5.58 mCi/ml, was used for metabolic 
labeling of the antigen.
3. Serum samples: Serum samples and relevant clinical
information were provided by the Serum/Tissue Bank of the 
Department of Microbiology and Immunology, EVMS. All 
patients were previously untreated when the sera were 
donated. Serum samples were stored at -70*C until used.
The PSA results for these samples, using Tandem-R PSA 
immunoradiometric assay (Hybritech, San Diego, CA), were 
provided by the Clinical Immunology Laboratory, Department 
of Microbiology and Immunology, EVMS.
B. METHODS
1. LNCaP cell culture. LNCaP cultured cell line, 
obtained from American Type Culture Collection (ATCC, 
Rockville, MD), was maintained in RPMI-1640 medium (Sigma) 
supplemented with 1 0 % heat inactivated bovine calf serum 
(HyClone, Logan, UT), 1 nM dihydrotestosterone, 1 mM L- 
glutamine and 50 pq/ml gentamicin (Sigma). The culture was 
kept in a humidified atmosphere of 5% CO2 in air at 37 *C 
(44-48). The cells were transferred at weekly intervals 
using simple dispersing by pipetting or 0 .0 1 % 
(ethylenedinitrilo)-tetraacetic acid disodium salt (EDTA, 
Mallinckrodt) in phosphate-buffered saline (PBS, 136 mM 
NaCl, 2.7 mM KC1, 8 mM Na2HP04, 1.5 mM KH2PO4 , 0.9 mM CaCl2, 
0.5 mM MgCl2, pH 7.4).
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2. Tissue extracts. Tissue extracts of the LNCaP 
xenograft tumor were prepared by first finely mincing the 
tissue in 10 ml of 1.0 mM NaHC0 3  buffer containing 200 /j1 of 
a 50 x protease inhibitor cocktail (antipain 1.7 mg, 
pepstatin 5.0 mg, EDTA 186 mg dissolved in 10 ml distilled 
water). The tissue was then homogenized in the buffer by a 
Polytron homogenizer (Brinkman, NY). The homogenate was 
spun at 2 x 103 g, 4‘C for 5 minutes, and the supernatant 
was further spun at 1.38 x 105 g, 4*C for 2 hours. The 
resulting pellet was resuspended in a minimum volume of PBS 
and stored at ~70*C (37, 49, 50). This pellet, membrane- 
enriched fraction, was the antigen-enriched preparation and 
was used for purification of the 7E11-C5 antigen. Protein 
concentrations were determined by a bicinchoninic acid (BCA) 
protein assay (Pierce) with bovine serum albumin (BSA,
Sigma) as the standard (51) and the 7E11-C5 antigen activity 
was determined by radioimmunoassay.
3. Antibody iodination. The antibodies, including 
rabbit anti-mouse IgG (H+L) polyclonal antibody and 7E11-C5 
MAb, were labeled with 125i using the chloramine T method 
(52, 53). Briefly, 10 (il of Na-125I in 0.01 N NaOH 
(approximately 250 nCi) were neutralized with the same 
volume of 0.01 N HC1 in a tube. To this solution was added 
20 jil PBS and 122.5 fiq antibody in 50 fil PBS. The reaction 
was initiated with 21.6 /xl of freshly prepared chloramine T 
(4 mg/ml). The mixture was allowed to incubate for 1 minute
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with gentle shaking. At this point, 90 pi sodium 
metabisulfite (2.4 mg/ml) was added to the mixture and 
incubated for 10 seconds. The reaction was then quenched 
with 180 fil sodium iodide (10 mg/ml). The reaction mixture 
was transferred to a Ultrafree-MC filter unit (Millipore, 
Bedford, HA) for membrane ultrafiltration in order to 
separate bound versus unbound label. The reaction mixture 
was transferred to the upper chamber of the filter and the 
filter was centrifuged at 2 x 103 g for 25 minutes. The 
upper chamber was then transferred to a fresh 
microcentrifuge tube and the volume of the filtrate was 
determined. An aliquot of PBS, equal to the filtrate 
volume, was added to the concentrate to initiate the wash 
steps. This procedure was repeated twice. After the final 
wash, the concentrate was measured for retained volume and 
transferred to a storage tube. The entire iodination 
procedure was performed at room temperature. Total 
radioactivity was then counted and trichloroacetic acid 
(TCA, Hallinckrodt) precipitation assay was carried out to 
determine the 1 2 5 I-antibody coupling efficiency. For this 
procedure, 1 0 0 Ml of 1 :1 , 0 0 0  diluted labeled antibody 
solution were incubated with an equal volume of 20% TCA for 
15 minutes at 4’C. After centrifuging for 1 0 minutes, 
radioactivities of the supernatant and diluted sample were 
determined and the TCA precipitation percent was calculated 
using the following formula:
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total sample cpm - supernatant cpm
precipitation %  ------------------------------------- x 1 0 0
total sample cpm
For both antibodies, the TCA precipitation percents were 
usually over 85%.
4. Radioimmunoassay. The 7E11-C5 antigen preparation 
was added to the wells of a 96-well microtiter plate (Becton 
Dickinson, Oxnard, CA) at 3-5 /xg protein/25 /xl/well. The 
plate was air-dried and fixed with 50 jxl of PBS containing 
0.1% glutaraldehyde (Fisher) for 5 minutes and blocked with 
50 /xl of normal saline containing 10% normal horse serum and 
0.1% sodium azide for at least l hour. Primary antibody, 
7E11-C5 MAb (20 /ig/ml), was added at 25 /xl/well, and the 
plate was incubated for 1 hour. The unbound MAbs were 
removed by washes with washing buffer (normal saline 
containing 1 % normal horse serum and 0 .1 % sodium azide).
The secondary antibody, 1 2 5 I-labeled rabbit anti-mouse IgG 
(H+L) , was added at 105 counts per minute (cpm)/25 jxl/well 
and the plate was incubated at room temperature for another 
hour. The unbound labeled antibodies were removed by 
washing three times with the washing buffer. The plate was 
air-dried, the wells were cut, and the radioactivity was 
measured in a gamma-counter (36). Culture supernatant from 
P3X63Ag8, a non-IgG-secreting subclone of the murine myeloma 
cell line (54), was used as a negative control and all tests 
were performed at least in duplicate.
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5. Antigen solubilization. The tissue extracts (3.5 
mg/ml) were treated with three detergents, including NP-40, 
CHAPS and Glucoside at different concentrations, for 1 hour 
at 4*C. The sample was spun at 105 g, 4'C for 1 hour, and 
the supernatant and pellet harvested. The protein 
concentration was determined by the BCA protein assay and 
the antigen activity was determined by radioimmunoassay.
One unit of antigen was defined as lo4 cpm (55-59).
6 . Molecular exclusion chromatography. Three molecular 
exclusion columns were evaluated for separating the antigen 
from contaminating materials, including Sephadex G-100 with 
a fractionation range of molecular weight (MW) 4,000- 
150,000, Sephadex G-200 with a range of MW 5,000-600,000, 
and Sephacryl S-300 with a range of MW 10,000-1,500,000.
The detergent solubilized LNCaP tissue extracts (2.1- 
2 . 6  mg/ml) were loaded on the column and the sample volumes 
were always less than 5% of the column bed volume. The 
running buffer was 10 mM Tris-HCl, pH 7.5, 145 mM NaCl and 
flow rate was controlled by using a peristaltic pump (ISCO, 
Lincoln, NE). All column procedures were carried out at 
4*C. Protein concentrations of the collected fractions were 
determined by UV 280 nm absorbance and the antigen activity 
was assayed by radioimmunoassay (60).
7. Ion exchange chromatography. A DEAE-Sepharose CL-6B 
column was equilibrated with 10 mM Tris-HCl buffer, pH 7.8
R eproduced with perm ission of the copyright owner. Further reproduction prohibited without perm ission.
1 8
and 20 ml of solubilized LNCaP tissue extract (4.6 mg/ml) 
was loaded onto the column. After the sample entered the 
column, the column was washed with 1 bed volume of 
equilibrating buffer. The elution conditions were as 
follows: 10 mM Tris-HCl, pH 7.8, 0.08 M NaCl followed by 10 
mM Tris-HCl with a 0.08 M to 0.2 M NaCl gradient, pH 7.8, 
and a final elution buffer of 10 mM Tris-HCl, pH 7.8 
containing 1.0 M NaCl. The fractions were collected and 
measured for protein concentration by absorption at OD 280 
nm and the antigen activity for selected fractions (protein 
peaks and shoulders) were tested by radioimmunoassay. The 
entire procedure was carried out at 4*C (31, 61).
8 . Immunoaffinity chromatography.
a. Elution buffer: Screening for a suitable elution
buffer was performed using a modified radioimmunoassay to 
test antigen stability in elution buffer. One hundred 
microliters of test buffer were added to the wells of 96- 
well antigen-coated plate and incubated for 2 hours at room 
temperature. PBS was used as control. The plate was then 
subjected to a standard radioimmunoassay with the 7E11-C5 
MAb as primary antibody. Percent of antigen stability for 
each buffer was calculated using the following formula:
cpm from buffer treated wells
% Ag stability  -----------------------   x 100
cpm from PBS treated wells
To determine the efficiency of test buffer in 
disassociating the antibody/antigen binding, 25 ^1 of 7E11-
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C5 MAb (20 /ig/ml) was added to the 7E11-C5 antigen coated 
wells and incubated for 1 hour and washed. The test buffer, 
1 0 0  /il/well, was then added to the wells and incubated for 2 
hours. PBS was used as the control. After washing three 
times with washing buffer, the 1 2 5 I-labeled secondary 
antibody (rabbit anti-mouse IgG) was added and incubated for 
another 1 hour. The radioactivity was determined after 
washing three times and the antigen elution percent for each 
buffer was calculated using the following formula:
cpm from buffer treated wells
% Ag elution = (1  ------------------------   ) x 100
cpm from PBS treated wells
b. Column preparation: An ImmunoPure Ag/Ab
immobilization Kit #1 column was used and the 7E11-C5 MAb- 
matrix coupling protocol was performed according to the 
manufacturer's instructions. Briefly, the 2 ml-column was 
prepared by equilibrating the gel with 6 ml of coupling 
buffer (0.1 M phosphate, pH 7.0, 0.05% sodium azide), then 
the bottom of column was sealed, and 2 ml of the 7E11-C5 MAb 
solution (10 mg/ml) were added to the equilibrated column. 
The reducing reagent, 200 /il of 6.4% sodium cyanoborohydride 
(NaBH3CN) in 0.01 N NaOH, was added to the column. The 
column was sealed and mixed by gentle up-down shaking for 2 
hours at room temperature. The reaction was then allowed to 
proceed for another 4 hours without shaking. The effluent 
was collected and the column was washed with 4 ml of the 
coupling buffer. The wash buffer was combined with the
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effluent and used to determine the coupling efficiency. The 
column was then equilibrated with 4 ml of quenching buffer 
(1.0 M Tris-HCl, pH 7.4) and sealed. The quenching buffer 
(2.0 ml) and 200 fil of the reducing buffer (6.4% NaB^CN in
0.01 N NaOH) were added and the gel was mixed again by 
gentle shaking for 30 minutes at room temperature, followed 
by washing with 20 ml of washing buffer (1.0 M NaCl) and 20 
ml of storage buffer (0.05% sodium azide). The column was 
stored at 4*C with the storage buffer (62).
c. Antigen purification: After the 2 ml immunoaffinity
column was equilibrated with running buffer (normal saline), 
1 ml of the solubilized LNCaP tissue extracts (4.2 mg/ml) 
was allowed to enter the gel and the column was sealed and 
incubated at room temperature for 1 hour. The column was 
then washed with 2 0 ml ( 1 0 column bed volumes) of running 
buffer to remove nonspecific molecules. Eight microliter (4 
bed volume) of the elution buffer (2.0 M MgCl2 , pH 5.6) were 
then used to elute the antigen from the column. The 
fractions collected were monitored for protein by OD 280 nm 
absorbance and tested for the 7E11-C5 antigen activity by 
radioimmunoassay using the elution buffer as a control (63- 
66).
9. HPLC. Before HPLC fractionation, the antigen 
positive fractions collected from the immuoaffinity column 
were pooled and dialysed against HPLC running buffer (normal 
saline) overnight at 4°C. The sample was then concentrated
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by membrane ultrafiltration using Centriprep-30 concentrator 
(MW 30,000 cut-off, Amicon, Beverly, MA). Some samples also 
were concentrated by an absorption method (67, 6 8 ). The 
sample was placed in dialysis tubing which was then placed 
in a dry bed of high molecular weight polyethylene glycol 
(PEG, MW 8,000, Sigma) until concentration was completed. 
After the HPLC gel filtration column was equilibrated with 
running buffer, 2 ml of the desalted and concentrated sample 
(30 /ig/ral) prepared as described above were applied to the 
column. The protein concentrations were monitored at OD 280 
nm. The peak fractions were tested by radioimmunoassay for 
antigen activity and the HPLC running buffer was used as 
control (69). A flow chart for purifying the 7E11-C5 
antigen is shown in Figure 1.
10. Peptide Sequencing. The HPLC purified 7E11-C5 
antigen samples were sent to the Protein and Nucleic Acid 
Sequencing Center at the University of Virginia, 
Charlottesville, VA. for determination of N-terminal amino 
acid sequence and amino acid composition of the antigen 
using a gas-phase sequencer (70).
11. Chemical and enzyme treatment. The 7E11-C5 antigen 
(LNCaP tumor tissue extracts or the immunoaffinity purified 
antigen) were treated with different chemicals and enzymes 
at varying concentrations in an Eppendorf tube for 24 hours 
at 37*C and then used to coat wells of microtiter plates.
PBS or relevant buffers were used as controls.
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Figure 1. Procedure for the 7E11-C5 Antigen Purification
LNCaP xenograft tissue 
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Radioimmunoassay was performed to determine the remaining 
antigen activity following each treatment. Percent control 
binding for each treatment was calculated using the 
following formula:
cpm of the reagent treated wells
% control binding  ----------------------------------- x 1 0 0
cpm of the PBS treated wells
Selected samples were also analyzed by Western blot in 
order to confirm the radioimmunoassay results (65, 6 6 , 71).
12. Competitive antibody binding assay. Varying 
concentrations (0 - 1 0 0 /xg/ml) of unlabeled antibody (blocking 
antibody) were added, 25 /xl/well, to the purified antigen- 
coated wells and incubated for 2 hours at room temperature. 
The blocking antibodies used were murine MAbs reactive with 
different prostate-associated antigens. These MAbs included 
anti-PAP, anti-PSA, anti-PSP, Turp-27, PD-41 and Leu-7 (72, 
73). The controls included PBS, unlabeled 7E11-C5 MAb, and 
normal murine IgGl, IgG2a, IgG3 and IgM. The 1 2 5 I-labeled 
7E11-C5 MAb (test antibody), at 50% maximal binding 
activity, was then added to the wells (5 x 105 cpm/25 
Ail/well) and incubated for another 2 hours. After washing 
three times with washing buffer, the radioactivity in the 
wells was determined. The percent inhibition was calculated 
using the following formula (31):
cpm of blocking antibody wells
% Inhibition = (1  -------------------------------- ) x 100
cpm of PBS wells
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13. Lectin competitive binding assay. Lectins were 
diluted to a concentration of 1.0 mg/ml in PBS, as suggested 
by the manufacturer, for maximal activity. Each lectin (100 
^1/well) was added to purified antigen-coated wells and 
incubated for 2 hours with PBS as control. After washing 
the wells three times, a standard radioimmunoassay was 
performed using 50% maximal binding titer of 7E11-C5 MAb as 
the primary antibody, and the percent control binding was 
calculated using the following formula (37):
cpm of the lectin treated well
% control binding  --------------------------------- x 1 0 0
cpm of PBS treated wells
A radioimmunoassay using 7E11-C5 MAb as the primary 
antibody, directed against lectin-coated wells, was carried 
out to determine whether or not the 7E11-C5 MAb was reactive 
to the lectin.
14. Carbohydrate competitive binding assay. Varying 
concentrations of carbohydrates, carbohydrate conjugates or 
PBS (control) were incubated with an equal volume of 7E11-C5 
MAb in Eppendorf tubes for 2 hours at room temperature. 
Following the incubation, 50 /il of this mixture was added to 
antigen-coated wells and incubated for 1 hour. Following 
three washes, 1 2 5 I-labeled rabbit anti-mouse IgG was added 
as in a standard radioimmunoassay. The percent control 
binding for each carbohydrate was calculated using the 
following formula (37):
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cpm of carbohydrate treated wells
% control binding  ---------------------------------- x 1 0 0
cpm of PBS treated wells
15. Sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) and Western blot analysis (74- 
77). SDS-PAGE was performed using a 160 x 180 x 1.5 mm gel 
(4% stacking and 10% resolving). Samples were diluted with
sample buffer (0.5 M Tris-HCl, pH 6 .8 , 2% SDS, 5% 2-
mercaptoethanol, 10% glycerol, 0.05% bromophenol blue), 
heated at 100*C for 5 minutes and loaded onto the gel, 60-
100 fig protein/lane. The gel was run at 40 mA constant
current for 5 hours at 4*C with running buffer (Tris base 12 
g, glycine 57.6 g, SDS 4 g to 4,000 ml dH2 0 ). Molecular 
weight protein standards (Amersham) were used as a reference 
for migration of proteins and included myosin (MW 200,000), 
phosphorylase b (MW 92,500), BSA (MW 69,000), ovalbumin 
(46,000), carbonic anhydrase (MW 30,000), trypsin inhibitor 
(MW 21,500) and lysozyme (MW 14,300). The separated 
proteins were electrophoretically transferred to Immobilon-P 
PVDF (polyvinylidene difluoride) transfer membrane 
(Millipore) at 25 Volts, 4*C for 11 hours with transferring 
buffer (Tris base 15.15 g, glycine 72 g to 5,000 ml cH^O). 
Following transfer of the proteins, the membrane was blocked 
with 100 ml of PBS containing 5% BSA and 0.3% Tween-20 for 1 
hour at 37“C. The membrane was then incubated with 100 ml 
of 7E11-C5 MAb (20 /ig/ml) for 2 hours at room temperature 
with gentle agitation, followed by washing three times in
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PBS containing 0.05% Tween-20. After subsequent incubation 
with 1 2 5 I-labeled rabbit anti-mouse IgG (H+L) at 1 x 107 
cpm/ 1 0 0  ml for 1 hour and further washing three times, the 
membrane was air-dried and exposed to X-ray film (Eastman 
Kodak) at -70*C for one to four days.
16. Silver stain (78, 79). Following SDS-PAGE, the gel 
was fixed with 200 ml of 50% methanol containing 0.1% 
formaldehyde (Sigma) for 2 hours or overnight. The gel was 
then incubated with 200 ml of 0.005% dithiothreitol (DTT, 
Sigma) for 45 minutes, followed by incubation with 200 ml of
0.5% silver nitrate (Sigma) for another 45 minutes. The 
color was developed using 200 ml of 3% sodium carbonate 
(Mallinckrodt) containing 0.05% formaldehyde (freshly 
prepared). When the color developed to the desired point, 
it was stopped with 25 ml of 2.3 M citric acid (Sigma). The 
gel was washed three times with water and stored in water. 
The entire procedure was performed at room temperature and 
the gel was gently agitated during all incubations.
17. Glycolipid extracts. Glycolipid extractions from 
LNCaP tissue were carried out according to the method 
introduced by Clark et al. (80). Briefly, under oxygen 
exclusion conditions, the LNCaP tissue homogenate was 
treated with protease type XIV (10 mg/ml) and detergent 
(0.1% NP-40) at 55°C for 24 hours. The sample was then 
separated into phases by adding chloroform and methanol to 
obtain a final ratio of chloroform/methanol/buffer of
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4:8 :5.6 (v/v/v). The mixture was centrifuged at 3 x 103 g 
for 10 minutes and the upper layer was saved. The lower 
layer was treated with chloroform and methanol, and 
centrifuged again. The procedure resulted in the pooled 
upper layer fraction containing glycolipids with longer 
oligosaccharide chains (> 5 monosaccharides) and organic 
solvents, and the lower layer fraction containing 
glycolipids with shorter oligosaccharide chains (< 5 
monosaccharides) and detergent. The upper layer was then 
evaporated with nitrogen, dissolved in methanol/water (1 :1 , 
v/v) and applied to a Sep-Pak column (Ciq cartridges, 
Millipore) to separate the upper phase glycolipids from 
contaminating peptides, glycopeptides and salts. The lower 
layer was also evaporated with nitrogen, dissolved in 
chloroform and applied to a silica gel column (Silicic Acid, 
Bio-Sil A, 20-44 microns, BioRad) to separate the 
glycolipids from the contaminating detergent. The separated 
upper layer and lower layer samples were evaporated with 
nitrogen and then dissolved in chloroform/methanol (1 :1 , 
v/v) separately. The glycolipid samples (the upper layer 
and the lower layer) were used as targets in 
radioimmunoassay and for TLC and TLC immunoblot. The 
concentration of the glycolipids was determined by phenol- 
sulfuric acid assay. For this procedure, 100 fil of test 
sample were mixed with 6 jil of 90% phenol and 500 nl 
sulfuric acid, and the absorbance of the mixture was
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measured at OD 495 nm. Varying concentrations of D-glucose 
were used for generating a standard curve.
18. Thin-layer chromatography (TLC) and TLC immunoblot 
analysis (81). The extracted glycolipid samples (20 
Mg/lane) were carefully loaded on a TLC plate (TLC aluminium 
sheets silica gel 60, 10 x 10 cm, West Germany) and the 
plate was placed in tank containing a solvent system 
consisting of chloroform/methanol/water (5:4:1, v/v/v). The 
solvent was allowed to migrate to the top of the plate 
(approximately 1 hour), the plate was removed and air-dried. 
The plate was either visualized or further analyzed by 
immunoblot. To visualize the glycolipid bands on TLC, the 
plate was evenly sprayed with orcinol-H2S0 4 reagent (0 . 2 g 
orcinol in 11 ml sulfuric acid and 89 ml ethanol) and then 
activated by heating at 100*C for 5 minutes. Glycolipids 
gave pinkish violet bands on a white background. The 
procedure for the TLC immunoblot was the same as that for 
Western blot analysis described previously. Twenty 
micrograms of gangliosides (type II, purified from bovine 
brain, Sigma) were used as standard controls (82), and 
included at least 4 molecules, trisialoganglioside lb (G<nb# 
MW 2,100), monosialoganglioside 1 (Gjq, MW 1,540), 
sphingomyelin (MW 600) and N-acetylneuraminic acid (MW 309).
19. Antigen immunoprecipitation (83-85). The spent 
medium from LNCaP cells cultured in a 75-cm2 tissue culture 
flask was removed and the cells were washed once with
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methionine-free RPMI-1640 medium (Sigma). The methionine- 
free medium (5.0 ml) was added to the culture and incubated 
at 37°C overnight. After exchanging the medium for fresh 
methionine-free medium, 250 uci 3 5S-methionine was added to 
the culture and incubated at 37*C for 6-18 hours. The cells 
were then harvested and lysed with lysis buffer (145 mM 
NaCl, 0.5% NP-40, 50 mM Tris-HCl, pH 8.0). The cell lysate 
was collected and spun at 105 gr, 4*C for 30 minutes and the 
resulting supernatant was harvested. 7E11-C5 MAb (20 /ig/ml) 
was added to the supernatant (50 /il MAb/ml supernatant) and 
the mixture was incubated at 4*C for 1 hour to form an 
immune complex. To purify the immune complex, 10% Protein-A 
Sepharose CL-4B (Sigma) was added to the mixture (50 /il/ml) 
and the sample was kept at 4*C for 30 minutes. After 
washing three times with lysis buffer, the final pellet was 
treated with SDS-PAGE sample buffer, boiled, and analyzed by 
10% SDS-PAGE. The gel was then dried and autoradiography 
was carried out as described previously. Normal mouse IgGl 
was used as a control antibody.
20. Western blot analysis of serum samples. Serum 
samples from six categories, including normal males, BPH 
patients (biopsy proven) and CaP patients (stages A, B, c 
and D, biopsy proven) were analyzed by SDS-PAGE and Western 
blot. Since CaP is uncommon in men younger than age 50, 
normal serum samples were obtained from donors over 50 years 
of age (4). Eight serum samples were selected from each
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category and 4 /il of serum/lane was loaded onto the SDS-PAGE 
gel. LNCaP tissue extract, 80 /xg/lane, was used as a 
positive control. The electrophoresis and blotting
I O Cprocedures were the same as described previously. The 
labeled 7E11-C5 MAb was used for antigen detection and 1 2 5 i- 
labeled normal mouse IgGl used as control.
21. Competitive inhibition assay. One hundred 
microliters of test serum sample were incubated with an 
equal volume of 7E11-C5 MAb at room temperature for 3 hours. 
The MAb concentration was diluted to 50% of maximal binding 
as determined by previous binding tests. A diluent buffer, 
PBS containing 0.3% BSA, was used as a control. The mixture 
(50 jxl/well) was then added to the wells of 96-well plate 
coated with the purified 7E11-C5 antigen. The plate was 
incubated at 4'C for 18 hours. After washing three times 
with washing buffer, 1 2 5 I-rabbit anti-mouse IgG (H+L) was 
added to the wells and incubated at room temperature for 1 
hour. The percent inhibition for each serum sample was 
calculated using the following formula (43, 8 6 ):
cpm of serum + 7E11-C5 MAb
% Inhibition = (1  -------------------------------) x 100
cpm of diluent + 7E11-C5 MAb
The serum samples used in this study included normal 
female, normal male, BPH, all grades of CaP. Two to five 
serum samples were analyzed from each category.




A. Further determination of the specificity of the 7E11-C5 
antigen.
1. A previous immunohistochemical study demonstrated 
that the 7E11-C5 antigen was prostate organ-specific (43). 
In the present study, Western blot analysis of different 
tissue extracts and normal seminal plasma showed that the 
7E11-C5 antigen was only detected in the tissue extracts of 
LNCaP (the immunogen for generating the hybrid secreting 
7E11-C5 MAb), normal prostate, BPH, CaP and normal seminal 
plasma, but not in tissue extracts of normal lung, breast 
cancer and colon cancer (Figure 2). Under reducing 
conditions, the 7E11-C5 antigen exhibited a major 100-Kd 
band and a minor 70-Kd band. Some samples of normal 
prostate, BPH and CaP exhibited other high molecular weight 
bands (Figure 2) (87, 8 8 ). Western blot analysis also 
demonstrated that the 7E11-C5 MAb was not reactive with 
purified PAP and PSA (Figure 2). A nonspecific 55-Kd band 
seen on the blot was identified as endogenous human IgG 
heavy chain, because the rabbit anti-mouse antibody has 
minimal cross-reaction with human immunoglobulins.
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Figure 2. Specificity of the 7E11-C5 MAb as determined by 
Western blot analysis. Different tissue extracts, normal 
seminal plasma, and purified PAP and PSA antigens were 
subjected to 4-20% linear gradient SDS-PAGE. Tissue 
extracts and seminal plasma were applied at 60 fig 
protein/lane and purified antigen at 1 0 fig protein/lane.
The separated proteins were transferred to Immobilon-P 
membrane, and then analyzed for reactivity with 7E11-C5 MAb. 
SP, normal seminal plasma; NP, normal prostate; BP, benign 
prostatic hyperplasia; CaP. carcinoma of prostate; LNX.
LNCaP xenograft tumor; PAP, purified PAP; PSA, purified PSA; 
B, breast carcinoma; L, normal lung, C, colon carcinoma.
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2. Competitive antibody binding results showed that 
other antibodies (anti-PAP, anti-PSA, anti-PSP, Turp-27, PD- 
41 and Leu-7) (72, 73) were unable to block the binding of 
1 2 5 I-labeled 7E11-C5 MAb to its target antigen (Figures 3,
4, 5). Comparing the profiles of the 7E11-C5 antigen with 
PAP, PSA and PSP antigens on Western blot, the 7E11-C5 
antigen showed no similarity with these three major prostate 
markers (Figure 6 ). These results together strongly 
indicated that the 7E11-C5 antigen was an unique prostate 
organ-specific antigen.
B. Purification of the 7E11-C5 antigen (89).
1. Antigen solubilization. Three detergents, CHAPS, 
Glucoside and NP-40, were evaluated for their abilities to 
solubilize the 7E11-C5 antigen from the LNCaP tissue 
extracts. The result showed that 0.5% and 1% of NP-40 
appeared to be the best concentration for solubilizing the 
antigen (Table II), resulting in both the highest per cent 
recovery of protein in the supernatant as well as the 
highest antigen activity.
2. Molecular exclusion chromatography. Molecular 
exclusion columns (Sephadex G-100, Sephadex G-200 and 
Sephacryl S-300), separating molecules based on their sizes 
and shapes, were evaluated for purifying the antigen. The 
7E11-C5 antigen activity appeared primarily in the void 
volume, although the antigen activity shifted slightly
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Figure 3. Competitive binding radioimmunoassay of the 7E11- 
C5 MAb to its target antigen with MAbs to PAP, PSA and PSP. 
Varying concentrations (0-100 fxg/ml) of blocking antibodies, 
including unlabeled 7E11-C5 MAb (IgGl), anti-PAP (IgG2a), 
anti-PSA (IgGl) and anti-PSP (IgGl), were added to the 
purified 7E11-C5 antigen-coated wells and incubated at room
1 pctemperature for 2 hours, followed by adding of the 
labeled 7E11-C5 MAb (5 x 105 cpm/25 /il/well). After 
incubation for another 2 hours and three washes, the 
radioactivity in the wells was determined.
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Figure 4. Competitive binding radioimmunoassay of 7E11-C5 
MAb to its target antigen with MAbs to Turp-27, PD-41 and 
Leu-7. The procedure was the same as described in Figure 3 
The blocking antibodies were murine MAbs Turp-27 (IgG3), PD 
41 (IgGl), Leu-7 (IgM) and unlabeled 7E11-C5 MAb (IgGl),

















• — •  7E11-C5
o — o Turp—27









Competing Mab concentration (ug/ml)
R eproduced  with perm ission of the copyright owner. Further reproduction prohibited without perm ission.
Figure 5. Competitive binding radioimmunoassay of the 7E11- 
C5 MAb to its target antigen with different isotype-matched 
control murine antibodies. The procedure was the same as 
described in Figure 3. The blocking antibodies were normal 
mouse IgGl, lgG2a, IgG3, IgM and unlabeled 7E11-C5 MAb
( I g G l ) •

















• — •  7E11-C5 










Competing Mab concentration (ug/ml)
R eproduced with perm ission of the copyright owner. Further reproduction prohibited without perm ission.
5 0 - * -  m  
36-*- «*
16-*- m
1 2  3  ^
Figure 6. Comparison of the 7E11-C5 antigen with PAP, PSA 
and PSP by Western blot analysis. The samples were 
subjected to 6-20% linear gradient SDS-PAGE and then 
transferred to Immobilon-P membrane. Lane 1. LNCaP tissue 
extracts, 100 fig; lane 2 . normal seminal plasma, 20 fig; lane 
3., purified PSA, 7 fig, and lane 4 . purified PSP, 10 fig. The 
membrane was then cut into individual lanes and reacted with 
different antibodies separately; 7E11-C5 MAb for lane 1, 
anti-PAP MAb for lane 2, anti-PSA MAb for lane 3 and anti- 
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TABLE II
Comparison of Solubilization of the 7E11-C5 Antigen with
Different Detergents3
Protein in
supernatant Ag activity Ag activity
Detergent (mg/ml) % (unit/mg) (unit/ml)
PBS 0.5 - 20.0 9.9
10 mM CHAPS 1.3 27 30.7 39.9
20 mM CHAPS 1.4 30 23.3 32.6
30 mM Glucoside 1.35 28 57.7 77.8
0.5% NP-40 1.6 37 50.6 81.0
1% NP-40 1.5 33 65.0 97.5
10 mM CHAPS 
30 mM Glucoside 
0.5% NP-40 1.4 30 45.7 64.0
20 mM CHAPS 
30 mM Glucoside 
1% NP-40 1.35 28 29.4 39.7
a LNCaP tissue extract sample (3.5 mg protein/ml) was 
treated with a single detergent or combination of detergents 
at 4'C for 1 hour and spun at 105 g for 1 hour. Protein 
concentration of the supernatant was determined by the BCA 
protein assay. The 7E11-C5 antigen was tested by 
radioimmunoassay and one unit of the antigen was defined as 
10 cpm.
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beyond the void volume in Sephacryl S-300 separation, 
suggesting that the antigen molecule scarcely entered the 
pores of the gel matrices, even with the large fractionation 
range of the Sephacryl S-300. These results indicated that 
molecular exclusion chromatography was not suitable as a 
single step method for separating the 7E11-C5 antigen from 
contaminating materials (Figures 7, 8, 9).
3. Ion exchange chromatography. A DEAE-Sepharose CL-6B 
column, separating molecules based on charge differences, 
was used for purifying the 7E11-C5 antigen. The results 
(Figure 10) showed that the antigen was distributed widely 
throughout the entire separation with low antigen activity 
as compared with molecular exclusion chromatography.
4. Immunoaffinity chromatography. An immunoaffinity 
column was then used to purify the antigen as an alternative 
to molecular exclusion or ion exchange chromatography. The 
7E11-C5 MAb and gel matrix coupling procedure was performed 
according to the manufacturer's instructions with a coupling 
efficiency over 80%. The next step was to screen buffers 
for the ability to elute the antigen from the column. 
Modified radioimmunoassay procedures were used to test the 
antigen stability in test buffer and the ability of the 
buffer to disassociate the antigen/antibody binding.
Buffers with a high pH (pH 11.0) or a high salt 
concentration appeared to be potential candidates for 
antigen elution (Table III). However, a small-scale trial
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Figure 7. Purification of the 7E11-C5 antigen by Sephadex G- 
100. The Column was Sephadex G-100, 22 x 0.8 cm, with 
fractionation range (MW) of 4,000-150,000. The loading 
sample was 2.1 ml of solubilized LNCaP tissue extract (2.6 
mg/ml) and the running buffer was 10 mM Tris-HCl, pH 7.5, 
0.145 M NaCl with flow rate of 0.2 ml/minute. Fractions 
were collected at a volume of 1.5 ml/tube, the protein 
concentration measured by absorbance at UV A2 8 0 and 
antigen reactivity determined by radioimmunoassay.
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Figure 8. Purification of the 7E11-C5 antigen by Sephadex G- 
200. The column was Sephadex G-200, 22 x 0.8 cm, with 
fractionation range (MW): 5,000 - 600,000. The loading 
sample was 2.0 ml of solubilized LNCaP tissue extract (2.1 
mg/ml) and running buffer was 10 mM Tris-HCl, pH 7.5, 145 mM 
NaCl with flow rate of 0.2 ral/minute. Fractions were 
collected at a volume of 1.5 ml/tube, the protein 
concentration measured by absorbance at UV A2 8 O nm an(* 
antigen reactivity determined by radioimmunoassay.





























Figure 9. Purification of the 7E11-C5 antigen by Sephacryl 
S-300. The column was Sephacryl S-300, 75 x 1.6 cm, with 
fractionation range (MW): 10,000 - 1,500,000. The loading 
sample was 7.0 ml of solubilized LNCaP tissue extract (2.2 
mg/ml) and running buffer was 10 mM Tris-HCl, pH 7.5, 0.145 
M NaCl with flow rate: 0.6 ml/minute. Fractions were 
collected at a volume of 3.5 ml/tube, the protein 
concentration measured by absorbance at UV A2 8 O nitl and 
antigen reactivity determined by radioimmunoassay.






























Figure 10. Purification of the 7E11-C5 antigen by ion 
exchange chromatography. The column was DEAE-Sepharose CL- 
6B, 23 x 2.6 cm and loading sample was 20 ml of solubilized 
LNCaP tissue extracts (4.6 mg/ml). The equilibrating buffer 
was 10 mM Tris-HCl, pH 7.8 and the elution buffer was 10 mM 
Tris-HCl, pH 7.8, 0.08 M - 1.0 M NaCl gradient. Flow rate 
was 1.0 ml/minute and fractions were collected at a volume 
of 3.0 ml/tube. The protein concentration was measured by 
absorbance at UV A2 8 O nm and antigen reactivity determined 
by radioimmunoassay.
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Purification of the 7E11-C5 Antigen by Ion Exchange Chromatography
NaCI concentration (M)
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o.l M glycine, pH 2.5 62 61
0.15 M Na-citrate, pH 3.0 67 56
0.1 M Tris-HCl, pH 11.0 100 87
0.1 M triethylamine, pH 11.5 100 89
25% glycerol, pH 8.0 100 7
10% dioxane 32 77
2.0 M NaCl 100 64
2.0 M HgCl2 99 96
4.0 M MgCl2 96 93
5.0 M LiCl 97 56
a One hundred microliters of test buffer were added to the 
7E11-C5 antigen-coated wells and incubated at room 
temperature for 2 hours. PBS was used as control. The well 
was then washed and subjected to a standard radioimmunoassay 
with 7E11-C5 MAb as the primary antibody.
k Twenty five microliters of 7E11-C5 MAb (20 /xg/ml) were 
added to the antigen-coated wells, incubated at room 
temperature for 1 hour and washed. Test buffer was then 
added to the wells (100 ^1/well) and incubated for an 
additional 2 hours. PBS was used as control. The well was 
washed and 125I-labeled secondary antibody was added to the 
wells. After washes, radioactivity remaining in the wells 
was determined.
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showed that pH 11.0 buffers damaged the linkage of the 
antibody to the gel matrix, resulting in MAb being washed 
out of the column, while a buffer consisting of 2.0 M MgCl2 
proved to be able to effectively elute the antigen without 
releasing the antibody (data not shown).
Figure 11 illustrates purification of the antigen by 
immunoaffinity chromatography. After the elution buffer was 
added to the column, a small protein peak with high antigen 
activity (cpm value > 7,000) was released from the column. 
The purified antigen was desalted, concentrated and analyzed 
by SDS-PAGE. The Western blot and silver stain analyses of 
the 7E11-C5 antigen before and after immunoaffinity 
chromatography are shown in the Figure 12. The results 
confirmed that the 7E11-C5 antigen was successfully purified 
by immunoaffinity chromatography (Figure 12 A, lane A and 
B). It was noticed that after purification, the molecular 
weight profile of the antigen was changed, showing now that 
the purified antigen exhibited 100-Kd and 45-Kd bands 
instead of 100-Kd and 70-Kd bands. One explanation for this 
result might be that the high concentration of salt (2.0 M 
MgCl2) degraded the antigen. The blot also showed that 
there was no antigen detected in the non-absorbed fraction 
(Figure 12 A, lane C), indicating that the immunoaffinity 
column efficiently bound the antigen molecules in the 
loading sample. PAGE silver stain analysis showed that 
besides the 100-Kd band, there were several other protein
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Figure 11. Purification of the 7E11-C5 antigen by 
immunoaffinity chromatography. A 2 ml-column prepared from 
an immunoPure Ag/Ab Immobilization Kit #1 was loaded with 1 
ml of solubilized LNCaP tissue extract (4.2 mg/ml). The 
washing buffer was normal saline (145 mM NaCl, pH 7.0) and 
the elution buffer was 2.0 M MgCl2 , pH 5.6. Flow rate was
0.6 ml/minute and fractions were collected at a volume of 
1.0 ml/tube. The protein concentration was measured by 
absorbance at UV A2 8 O nm anc* antigen reactivity determined 
by radioimmunoassay.
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Figure 12. SDS-PAGE analysis of LNCaP tissue extracts and 
the eluate from immunoaffinity column. 7E11-C5 antigen 
containing samples were separated by 10% SDS-PAGE and then 
the 7E11-C5 MAb reactive components determined by Western 
blot analysis, protein identified following silver staining. 
(A) Western blot: lane A . solubilized LNCaP tissue extract,
60 nq; lane B . the eluate from immunoaffinity column, 10 yg; 
lane C . the non-absorbed proteins from immunoaffinity 
column, 60 /ig. (B) Silver stain: lane A . molecular weight 
markers (Kd)? lane B . solubilized LNCaP tissue extract, 60 
jig? lane C . the eluate from immunoaffinity column, 10 f*g.
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bands (Figure 12 B, lane C), indicating that the purified 
antigen was not totally pure.
A quantitative comparison (Table IV) showed that, 
following the purification protocol, approximately a 400- 
fold antigen purification from the LNCaP tissue homogenate 
was achieved and approximately 64% of the antigen was 
recovered.
5. HPLC. The eluate from the immunoaffinity column was 
desalted, concentrated and further purified by HPLC 
molecular exclusion. Figure 13 shows that a single peak 
with high antigen activity was eluted by HPLC. Based on a 
comparison with the standard controls, the molecular weight 
of the peak corresponded to approximately 500-Kd, indicating 
the molecular weight of 7E11-C5 antigen was about 500-Kd in 
its native state.
The HPLC purified samples were analyzed by a gas-phase 
sequencer for determination of N-terminal amino acid 
sequence and amino acid composition of the antigen, but the 
results were inconclusive because of the insolubility of the 
antigen. The sample requirements for the sequence analysis 
are that protein must be pure, soluble and without any 
contamination of detergents or salts. A high percent (77%) 
of the purified 7E11-C5 antigen becomes insoluble again 
after removing the detergent during the desalting and 
concentration procedures, resulting in a soluble protein
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TABLE IV


















lb 24 312 52 - 16,380 -
2 20 260 62 1.2 15,990 97.6
3 7 70 190 3.7 13,293 81.2
4 6 30 350 6.7 10,509 64.2
5 45 0.514 20,446 393 10,509 64.2
a Wet weight of the original LNCaP tissues was 2.4 g. 
Protein concentrations were determined by the BCA protein 
assay. The 7E11-C5 antigen was quantitated by 
radioimmunoassay and one unit of antigen was defined as 10 
cpm.
b 1, LNCaP tissue homogenate; 2, supernatant from the 
first centrifugation; 3, pellet from the second 
centrifugation; 4, supernatant from NP-40 solubilization; 5, 
eluate from immunoaffinity column.
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Figure 13. Purification of the 7E11-C5 antigen by HPLC. The 
column was an HPLC molecular exclusion column, 300 x 7.5 mm 
with fractionation range (MW) of 1,350-670,000. The loading 
sample was 2 ml of desalted and concentrated eluate from 
immunoaffinity chromatography (12 fig/ml) and the running 
buffer was normal saline (145 mM NaCl, pH 7.0). Flow rate 
was 1.0 ml/minute, protein concentration measured by 
absorbance at UV A 2 8 O nm and antigen reactivity determined 
by radioimmunoassay.
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concentration too low to effectively conduct the sequence 
analysis (data not shown).
C. Characterization of the 7E11-C5 antigen (89).
The 7E11-C5 antigen reactivity was tested after the 
antigen was subjected to various treatments. Both the 
immunoaffinity purified antigen and the crude antigen (LNCaP 
tissue extract) were used for this portion of the study and 
the experiments were carried out using a modified 
radioimmunoassay.
1. Physical and chemical treatment. Table V showed 
that although the antigen was resistant to 100*C for 10 
minutes, it was sensitive to heating at 100*C for 1 hour, a 
condition which severely denatures proteins. Periodate 
(NaI0 4 ) treatment, which oxidizes and cleaves sugar residues 
from glycoproteins, reduced the 7E11-C5 antigen activity, 
indicating that carbohydrate was involved in the antigenic 
determinant. The antigen activity remained unchanged after 
treatment with SDS or 2-mercaptoethanol. The antigen was 
sensitive to acid conditions but resistant to basic 
conditions. These results were confirmed by Western blot 
analysis (Figure 14).
2. Proteolytic treatment: The 7E11-C5 antigen was 
sensitive to all five proteases tested. It was noticed that 
there was a linear relationship between the concentration
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TABLE V
Physical and Chemical Treatment of the 7E11-C5 Antigen3
Treatment Condition
% control binding13 
crude Ag pure Ag
heat 100*C, 10 minutes 94 NTC
100*C, l hour 20 4
periodate 5 mM 36 NT
10 mM 39 NT
20 mM 37 NT
SDS 1% 140 113
5% 98 112
2-mercaptoethanol 1.25% 94 93
HC1 0.1 N 47 NT
1 N 38 38
NaOH 0.1 N 100 91
1 N 139 99
3 For chemical treatment, the 7E11-C5 antigen activity was 
tested by radioimmunoassay after the antigen was treated 
with a chemical at 37*C for 24 hours. PBS was used as 
control.
b crude Ag, LNCaP tissue extracts; pure Ag, immunoaffinity 
purified antigen.
c NT, not tested.
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Figure 14. Western blot analysis: Chemical and enzyme 
treatment of the 7E11-C5 antigen. The 7E11-C5 antigen 
(LNCaP tissue extract) was treated with various chemicals or 
enzymes for 24 hours at 37*C and then subjected to 10% SDS- 
PAGE, 80 /zg/lane, and Western blot. Lane A . PBS control; 
lane B . trypsin 100 U/ml; lane C . trypsin 1,000 U/ml; lane 
D, chymotrypsin 0.5 U/ml; lane E . chymotrypsin 5 U/ml; lane 
F, 0.1 N HC1, pH 2.0; lane G . 0.1 N HC1, pH 4.0; lane H . 0.1 
N NaOH, pH 9.0; lane I. 0.1 N NaOH, pH 11.0; lane J . 2 mM 
periodate; lane K . 20 mM periodate; lane L . protease XXI 4 
mU/ml; lane M . protease XXI 40 mU/ml; lane N . protease XIV
0.01 mg/ml; lane O . protease XIV 0.1 mg/ml; lane P . 
neuraminidase 0.01 U/ml and lane O . neuraminidase 0.1 U/ml.
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increase of the proteases tested and the decrease of the 
remaining antigen activity (Table VI). These results were 
confirmed by Western blot analysis (Figure 14), strongly 
indicating that protein played an important role in the 
antigenic determinant. The sensitivity of the 7E11-C5 
antigen to both periodate oxidation and protease treatment 
suggests that the antigen is a glycoprotein.
3. Glycosidase treatment. Glycosidases hydrolyze 
specific sugar residues from glycopeptides or glycoproteins. 
Various glycosidase treatments were carried out to determine 
the specificity of the carbohydrate involved in the 7E11-C5 
antigenic determinant. Table VII and Figure 15, lane B and 
C showed that the antigen was sensitive to beta- 
galactosidase. Galactosidase catalyzes the release of 
galactose residues from galactose conjugates, which suggests 
that galactose is a major component of the antigenic 
determinant.
4. Competitive binding experiments with lectins and 
carbohydrates. Lectins non-covalently bind to specific 
carbohydrate groups. The specificity of the carbohydrate 
involved in the antigen epitope was tested by using various 
lectins to block the binding of 7E11-C5 MAb to its target 
antigen. The results (Table VIII) showed that D-galactose- 
binding lectins (MPA, PNA) and N-acetyl-D-galactosamine- 
binding lectins (DBA and SBA) reduced the binding of 7E11-C5 
MAb to the target antigen, suggesting that galactose and
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TABLE VI
Proteolytic Enzyme Treatment of the 7E11-C5 Antigen3
Hydrolysis % control binding*5
Enzyme specificity0 Concentration crude Ag pure Ag
trypsin Lys, Arg 0.1 U/ml NT 95
1 U/ml NT 84
10 U/ml NT 32
100 U/ml NT 11
chymotrypsin Tyr, Phe, Trp 5 mU/ml NT 92
50 mU/ml NT 16
500 mU/ml NT 7
protease XIV broad spectrum 2 mg/ml 25 NT
protease XXI casein 2 mU/ml 98 87
20 mU/ml 66 70
200 mU/ml 17 18
protease XXVII broad spectrum 8 mU/ml NT 27
80 mU/ml NT 25
800 mU/ml NT 8
3 The 7E11-C5 antigen activity was tested by 
radioimmunoassay after the antigen was treated with various 
enzymes at 37*C for 24 hours. PBS was used as control.
b crude Ag, LNCaP tissue extracts; pure Ag, immunoaffinity 
purified antigen.
° Lys, lysine; Arg, arginine; Tyr, tyrosine; Phe, 
phenylalanine; Trp, tryptophan.
d NT, not tested.
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TABLE VII
Glycosidase Treatment of the 7E11-C5 Antigen3
Digestion % control binding*3
Enzyme specificity0 Concentration crude Ag pure Ag
neuraminidase NeuNAc 0.1 U/ml 97 115
1 U/ml 100 108
beta- beta-D-
galactosidase galactoside 1 mU/ml 136 115
10 mU/ml 112 101
100 mU/ml 73h 801,000 mU/ml NT 63
alpha-L- P-n itropheny1
fucosidase alpha-L-fucoside 50 mU/ml NT 98
500 mU/ml NT 96
O-glycanase gal-beta-
(1*3)-galNAc 5 mU/ml 97 103
10 mU/ml 101 100
N-glycanase Asn-linked sugars 1 U/ml 93 97
2 U/ml 100 101
Endo F keratin sulfate 5 mU/ml 100 108
50 mU/ml 96 112
chondroitinase chondroitin
ABC A, B and C 5 mU/ml 81 103
50 mU/ml NT 107
3 The 7E11-C5 antigen activity was tested by a 
radioimmunoassay after the antigen was treated with various 
enzymes at 37*C for 24 hours. PBS was used as control. For 
O-glycanase, beta-galactosidase and Endo F treatment, the 
samples were pre-treated with neuraminidase (l U/ml) at 37*C 
for 2 hours.
b crude Ag, LNCaP tissue extracts, pure Ag, immunoaffinity 
purified antigen.
c NeuNAc, N-acetylneuraminic acid; Endo F, Endo-beta-N- 
acetylglucosaminidase F; Asn, asparagine.
^ NT, not tested.
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Figure 15. Western blot analysis: Enzymatic deglycosylation 
of the 7E11-C5 antigen. The 7E11-C5 antigen (LNCaP tissue 
extract) was treated with various glycosidases at 37*C for 
24 hours. The samples were then subjected to 10% SDS-PAGE 
gel (80 jig/lane), transferred to Immobilon-P membrane and 
analyzed for reactivity with 7E11-C5 MAb. lane A . PBS 
control; lane B. beta-galactosidase 100 mU/ml; lane c. beta- 
galactosidase 1,000 mU/ml; lane D. alpha-L-fucosidase 100 
mU/ml; lane E . alpha-L-fucosidase 1,000 mU/ml.
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TABLE VIII
Competitive blocking of 7E11-C5 MAb Binding to 








DBA alpha-D-galNAc, D-gal 47
SBA alpha-D-galNAc, D-gal 64
con A alpha-D-man, alpha-D-glc 89
GS II D-glcNAc 89
WGA (D-glcNAc)2 , NeuNAc 90
UEA I alpha-L-fuc 92
LPA NeuNAc, D-galNAc, D-glcNAc 100
PHA oligosaccharide 100
a One hundred microliters of competing lectin (1 mg/ml) 
were added to purified antigen coated wells and incubated at 
room temperature for 2 hours. PBS was used as control. A 
radioimmunoassay was then performed using the 7E11-C5 MAb as 
primary antibody.
b gal, galactose; galNAc, N-acetyl-D-galactosamine; man, 
mannose; glc, glucose; glcNAc, N-acetyl-D-glucosamine; Fuc, 
fucose; NeuNAc, N-acetyl-Neuraminic acid.
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N-acetyl-D-galactosamine (galNAc) are part of the antigenic 
determinant. A result from control experiment showed that 
the 7E11-C5 MAb did not cross-react with the lectins (data 
not shown).
Different carbohydrates and carbohydrate conjugates, 
were tested for their ability to block the antigen-binding 
site of the MAb 7E11-C5. The results (Table IX) showed that 
none of the carbohydrates or carbohydrate conjugates tested 
were able to reduce reactivity of the 7E11-C5 MAb.
5. Treatment of the 7E11-C5 antigen with organic 
solvents. Organic solvents can be used to solubilize 
hydrophobic membrane proteins and extract the glycolipid 
fraction from tissue homogenates. Various solvents were 
tested for their effects on the 7E11-C5 antigen and the 
results (Table X) showed that the antigen reactivity was 
reduced by some solvents, such as chloroform, acetic acid 
and phenol.
6. Glycolipid. In order to determine whether or not 
the 7E11-C5 antigen was glycolipid in nature, chloroform- 
methanol glycolipid fractions were extracted from LNCaP 
tissue homogenates and tested for 7E11-C5 antigen activity. 
Radioimmunoassay results gave a negative result (data not 
shown) and TLC and TLC immunoblots (Figure 16) further 
confirmed that the 7E11-C5 antigen was not demonstrable in 
glycolipid extracts of LNCaP tissue.
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TABLE IX
Competitive Blocking of 7E11-C5 MAb to its Target Antigen 
with Carbohydrates or Carbohydrate Conjugates3
Carbohydrate0 MW Concentration
% control binding13 
crude Ag pure Ag
galactose 180.2 0.125 M 98 102
0.25 M 100 100
0.5 M 100 117
galNAc 221.2 0.125 M 99 107
0.25 M 102 108
0.5 M 98 96
glcNAc 221.2 0.1 M 87 99
melibiose 360.3 0.1 M 100 95
D-mannose 180.2 0.1 M 91 89
lactose 360.3 0.1 M 90 109
L-fucose 164.2 0.1 M 96 100
D-glucose 180.2 0.1 M NTd 106
stachyose 666.6 0.1 mg/ml NT 102
1 mg/ml NT 110
lacNAc 383.4 0.1 mg/ml NT 94
1 mg/ml NT 89
D-raffinose 594.5 0.1 mg/ml NT 96
1 mg/rol NT 95
beta-D-gal-
(1-3)-D-galNAc 383.4 0.1 mg/ml NT 83
1 mg/ml NT 94
a The carbohydrate or carbohydrate conjugate was incubated 
with an equal volume of the 7E11-C5 MAb at room temperature 
for 2 hours and PBS was used as control. A radioimmunoassay 
was then performed using 50 {il of the mixture as primary 
antibody.
b crude Ag, LNCaP tissue extracts; pure Ag, immunoaffinity 
purified antigen.
c galNAc, N-acety1-D-galactosamine; glcNAc, N-acetyl-D- 
glucosamine; lacNAc, N-acetyllactosamine; beta-D-gal” (l-3)- 
D-galNAc, 2-acetamido-2-Deoxy-3-0-beta-D-galactopyranosyl-D- 
galactopyranose.
° NT, not tested.
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TABLE X
Treatment of the 7E11-C5 Antigen with Organic Solvents3
Solvent Percentage % control binding
Chloroform 100 45
Acetic acid 50 31
100 29
Aqueous phenol 100 9
Formamide 50 90
100 58









3 The remaining 7E11-C5 antigen activity was tested by a 
radioimmunoassay after the antigen (LNCaP tissue extract) 
was treated with organic solvents at room temperature for 2 
hours. PBS was used as control.
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Figure 16. Thin-layer chromatography (TLC) and TLC 
immunoblot of LNCaP glycolipid extracts. TLC plates coated 
with silica gel were run in a solvent containing 
chloroform/methanol/water 5:4:1. Panel A: TLC immunoblot 
results and panel B: visualized TLC results. The numbered 
lanes contained the following samples: lane 1. tissue 
membrane protein 5 /ig/lane as positive control; lane 2. the 
upper layer glycolipid extracts 20 /ig/lane; lane 3. the 
lower layer glycolipid extracts 20 fig/lane; lane 4. 
glycolipid standard control (gangliosides) 20 Mg/lane. O, 
origin; SF, solvent front; trisialoganglioside lb;
GMl» monosialoganglioside 1.
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7. Immunoprecipitation. Immunoprecipitation of the 
7E11-C5 antigen was tried using several modified procedures. 
LNCaP cultured cells metabolically labeled with 35S- 
methionine showed little positive signal in the crude LNCaP 
cell lysate (data not shown), suggesting that 35S-methionine 
was unable to be incorporated by cultured LNCaP cells. 
Immunoprecipitation experiments failed to provide meaningful 
information after several attempts and using several 
modified procedures.
D. Detection of the 7E11-C5 antigen in serum samples.
1. Western blot analysis of serum samples. Forty-eight 
serum specimens were analyzed by Western blot analysis.
Eight samples from each of six categories, including normal 
males age 50 years or older, BPH patients (biopsy proven) 
and CaP patients (stages A, B, C and D, biopsy proven) were
tested. Table XI describes the sources of the various
samples tested, relevant clinical information and 
corresponding PSA values. Figure 17 shows the Western blot 
analysis of the serum samples. Compared to the positive 
control (LNCaP tissue extract, lane A), none of the 48 serum
samples showed clear positive bands, i. e. the 100-Kd and
70-Kd bands (Figure 17). There were some higher molecular 
weight bands observed in some samples, but theses bands were 
also identified on the antibody isotype-matched (normal 
mouse IgGl) control blot (Figure 18, B). Therefore, they
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TABLE XI










1 0201 N malec < 4.0
2 0206 N male < 4.0
3 0221 N male < 4.0
4 0225 N male < 4.0
5 0231 N male < 4.0
6 0250 N male < 4.0
7 0269 N male < 4.0
8 0271 N male < 4.0
9 5189 BPH 2.4
10 5191 BPH 2.8
11 5192 BPH 4.0
12 5193 BPH 1.7
13 5194 BPH 6.7
14 5195 BPH 6.7
15 5196 BPH 4.3
16 5197 BPH 12.9
17 4955 CaP A X 4.3
18 4956 CaP A X 21.2
19 4958 CaP A X 3.0
20 4960 CaP A X 0.6
21 4961 CaP A X 11.2
22 4962 CaP A X 41.0
23 4963 CaP A X 13.2
24 4964 CaP A X 18.5
25 4988 CaP B X 17.6
26 4989 CaP B X 10.3
27 4991 CaP B 1.2
28 4992 CaP B X 21.5
29 4995 CaP B X 2.5
30 4997 CaP B X 4.3
31 4998 CaP B X 7.2
32 5032 CaP B . X 52.2
33 5143 CaP C X 5.0
34 5171 CaP C X 69.5
35 5172 CaP C X 1.8
36 5173 CaP C X 79.4
37 5174 CaP C X 76.8
38 5176 CaP C X 229.0
39 5177 CaP C X 111.0
40 5179 CaP C X 345.0
continuing on next page












41 5017 CaP D X 20.9
42 5033 CaP D X 329.0
43 5039 CaP 0 X 32.7
44 5045 CaP D X 21.8
45 5058 CaP D X 13.8
46 5064 cap D X 15.4
47 6065 CaP D X 1,540.0
48 5066 CaP D X 6,246.0
a All diagnoses were pathologically proven and all 
patients were previously untreated when the sera were 
donated.
b WD, well differentiated? MD, moderately differentiated; 
PD, poorly differentiated.
c N male, normal male'. All were over 50 years old.
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Figure 17. Western blot analysis: Detection of the 7E11-C5 
antigen in serum samples. The serum samples were subjected 
to 10% SDS-PAGE, 4 ^il/lane. The separated proteins were 
transferred to Immobilon-P membrane and analyzed for 
reactivity to 125I-labeled 7E11-C5 MAb. Lane A was loaded 











B 0201 N male*3 < 4.0
C 0206 N male < 4.0
D 5196 BPH 4.3
E 5197 BPH 12.9
F 4955 CaP A X 4.3
G 4956 CaP A X 21,2
H 4998 CaP B X 7.2
I 5032 CaP B X 52.2
J 5177 CaP C X 111.0
K 5179 CaP C X 345.0
L 6065 CaP D X 1,540.0
M 5066 CaP D X 6,246.0
a WD, well differentiated? MD, moderately differentiated; 
PD, poorly differentiated. All diagnoses were 
pathologically proven and all patients were previously 
untreated when the sera were donated.
k N male, normal male. Both were over 50 years old.
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Figure 18. &, Western blot analysis of serum samples from 
normal female, normal male, BPH and CaP patients with 7E11- 
C5 MAb. The serum samples were subjected to 10% SDS-PAGE, 4 
Ml/lane. The separated proteins were transferred to 
Immobilon-P membrane and analyzed for reactivity to 125I- 
labeled 7E11-C5 MAb. Lane 1 was loaded with 80 /ig protein 
of cultured LNCaP cell extract as a positive control. fi, 
Western blot of the same samples as for &, but reacted with 
an isotype-matched negative control antibody (125I-labeled 











2 5221 N female*3
3 0201 N malec < 4.0
4 5196 BPH 4.3
5 4955 CaP A X 4.3
3 WD, well differentiated; MD, moderately differentiated; 
PD, poorly differentiated. All diagnoses were 
pathologically proven and all patients were previously 
untreated when the serum was obtained.
b N female, normal female.
c N male, normal male.




200* -  
100* -
70*-
1 2  3 4
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were not considered to be 7E11-C5 antigen.
2. Detection of the 7E11-C5 antigen in serum samples by 
a competitive binding radioimmunoassay. A modified 
competitive binding immunoassay was used to detect the 7E11- 
C5 antigen in serum samples. The samples were from normal 
female, normal male, BPH and all grades of CaP and two to 
five samples from each category were tested. The results 
(Table XII) showed that the percent inhibition was between 
52% to 65% with no significant differences regardless of the 
serum category. Even female serum samples showed similar 
positive results. In an attempt to increase the specificity 
of the immunoassay, a direct inhibition assay, instead of 
indirect inhibition assay, was used to test the serum 
samples. Table XIII shows that the percent inhibition was 
similar for both assays. The results obtained by the 
competitive inhibition assays together with the Western blot 
analysis suggest that other molecules, instead of the 7E11- 
C5 antigen, may nonspecifically interfere with the 7E11-C5 
MAb, resulting in the high percent of inhibition.
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TABLE XII
Detection of the 7E11-C5 Antigen in Serum Samples 









4912 N female0 55.3
4914 N female 56.5
0201 N male** < 4.0 65.6
0202 N male < 4.0 61.8
0204 N male < 4.0 58.6
0206 N male < 4.0 59.9
0207 N male < 4.0 64.5
5189 BPH 2.4 55.3
5191 BPH 2.8 59.1
5192 BPH 4.0 54.4
5193 BPH 1.7 61.0
5194 BPH 6.7 59.3
4956 CaP A X 21.2 54.2
4962 CaP A X 41.0 62.0
4965 CaP A X 0.9 58.0
4969 CaP A X 0.5 54.4
4973 CaP A X 30.6 56.8
4988 CaP B X 17.6 60.4
4989 CaP B X 10.3 58.9
4991 CaP B 1.2 56.0
4992 CaP B X 21.5 56.0
5032 CaP B X 52.2 53.1
4751 CaP C X 66.1 52.0
5172 CaP C X 1.8 58.7
5173 CaP C X 79.4 57.0
5176 CaP C X 229.0 63.2
5179 CaP c X 345.0 59.7
5033 CaP D X 329.0 49.2
5058 CaP D X 13.8 58.4
5065 Cap D X 1,540.0 61.3
5066 CaP D X 6,246.0 58.5
5068 CaP D X 415.0 56.0
continuing on next page
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% Inhibition: normal female — 55.9 + 0.6 SD
Normal male = 62.1 2.7 SD
BPH 57.9 + 2.6 SD
CaP stage A = 57.1 + 2.9 SD
CaP stage B = 56.9 ± 2.6 SD
CaP stage C = 58.1 + 3.7 SD
CaP stage D 56.7 + 4.1 SD
a The serum samples were tested by 7E11-C5 MAb inhibition 
assay as described in "Materials and Methods". All 
diagnoses were pathologically proven and all patients were 
previously untreated when the sera were donate.d.
k WD, well differentiated; MD, moderately differentiated; 
PD, poorly differentiated.
c N female, normal female.
^ N male, normal male. All were over 50 years old.
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TABLE XIII
Detection of the 7E11-C5 Antigen in Serum Samples by 







7E11-C5 inhibition %a 
direct assay indirect assay
0207 N male*3 < 4.0 41.5 49.8
5189 BPH 2.4 39.4 56.0
4962 CaP A 41.0 38.3 51.2
5065 CaP D 1,540.0 43.0 57.5
a Indirect competitive inhibition assay was described in 
"Materials and Methods", and in the direct assay, 125i- 
labeled 7E11-C5 MAb was used instead of unlabeled 7E11-C5 
MAb and I-labeled rabbit anti-mouse antibody. All 
diagnoses were pathologically proven and all patients were 
previously untreated when the serum was obtained.
k N male, normal male, over 50 years old.




Carcinoma of prostate (CaP) is the most common cancer 
in men, with well over 100,000 cases diagnosed in the United 
States in 1990. In nearly two thirds of the cases, the 
tumor had already spread beyond the prostate at the time of 
diagnosis. Since early-stage CaP can be effectively treated 
with radical prostatectomy and radiation therapy, early 
detection is essential in curbing CaP mortality (1-9).
The 7E11-C5 MAb described by Horoszewicz et aJL. (43), 
recognizes a prostate organ-specific antigen. ^^Tn-labeled 
7E11-C5 MAb has been shown to specifically localize in LNCaP 
tumors grown in nude mice (46) and in preliminary clinical 
investigations, 113Tn-labeled 7E11-C5 MAbs were also used to 
image human CaP metastases (90). In addition, the MAb was 
reported to detect shed 7E11-C5 antigen in the serum of 
patients with CaP (43). The previous report suggested that 
patients with positive serum levels were more likely to have 
progressive disease than those who had normal levels of 
7E11-C5 antigen expression (43). If these results could be 
verified, the 7E11-C5 antigen might be clinically useful for 
identifying CaP patients most likely to have a poor
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prognosis and who night be candidates for nore aggressive 
treatment. The objectives of the present study were 
undertaken to further determine the specificity of the 7E11- 
C5 antigen and to purify and biochemically characterize the 
antigen.
The previous 7E11-C5 MAb specificity studies (43) were 
carried out by immunohistochemical techniques (i. e. 
immunoperoxidase staining of tissue sections). In the 
present study, further evaluation of the specificity of the 
MAb 7E11-C5 was determined by Western blot analysis of 
extracts of LNCaP xenograft and human tissues and 
competitive binding experiments. Western blot analysis 
showed the presence of a 100-Kd band and a 70-Kd band in 
tissue extracts of LNCaP, normal prostate, BPH and CaP. 
Similar bands were detected in pooled normal seminal plasma, 
but not in any of the non-prostate tissue extracts tested. 
Since these bands were present under reducing conditions, it 
suggested the 7E11-C5 antigen consisted of two peptide 
chains. A competitive binding-inhibition study showed that 
antibodies to other prostate-associated antigens were unable 
to block the binding of 7E11-C5 MAb to its target antigen. 
Molecular weight comparisons, by Western blot, demonstrated 
that there was no similarity between the 7E11-C5 antigen and 
the other three major prostate-associated antigens, PAP, PSA 
and PSP. These results strongly indicate that the 7E11-C5
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antigen is a prostate organ-specific antigen and distinct 
from other known major prostate antigens (87-89).
The prostate organ-specific markers, PSA and PAP, 
particularly PSA, have been used clinically to provide both 
diagnostic and prognostic information about CaP. PSA has 
been considered to be the best overall serum marker for CaP, 
and some investigators even consider PSA to be the most 
meaningful and useful tumor marker available in cancer 
biology (91). However, the usefulness of PSA by itself as a 
marker for early detection and screening has at least two 
limitations. First, PSA is not prostate cancer-specific; it 
is prostate organ-specific, and numerous benign prostatic 
conditions can influence serum PSA levels. For example, 25% 
to 30% of men with BPH and without evidence of CaP had an 
elevated serum PSA level (17, 92). Second, not all CaP 
patients have an elevation in their serum PSA levels. In 
fact, 38% to 45% of men with CaP have serum PSA levels in 
the normal range (0 to 4 ng/ml) (92-96). A goal of the 
present study was to determine whether or not the 7E11-C5 
marker can provide any additional diagnostic or prognostic 
information in the management of CaP. Hopefully, a multiple 
marker system will provide more accurate information for CaP 
than presently available.
The major objectives to reach this goal were to purify 
and characterize the 7E11-C5 antigen. Since the LNCaP cell 
line was the immunogen for generating the hybrid secreting
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the 7E11-C5 MAb, LNCaP xenograft tissue homogenates were 
used as the source of crude antigen. The tissue homogenates 
were a mixture of all cell organelles with heterogeneity in 
both size and density. Partial separation of membrane 
proteins could be achieved on the basis of their density; 
with increasing centrifugal force, the cell debris, nuclei, 
mitochondria, lysosomes and microsomes can be sedimented in 
that order (97). In the present study, the preparation of 
LNCaP tissue extracts was based on this principle. Since 
the 7E11-C5 antigen is an insoluble, membrane-bound 
glycoprotein, the first low speed spin was, therefore, 
designed to remove the cell debris, nuclei and mitochondria 
and the second high speed and longer centrifugation was used 
to concentrate the membrane-bound proteins in a pellet by 
removing the soluble molecules (42).
Proteins are fragile molecules that require care during 
purification to ensure that they remain intact and fully 
active. Therefore, in order to minimize proteolysis and 
prevent protein denaturation from endogenous proteases in 
the LNCaP tissue homogenate, a protease inhibitor cocktail, 
including antipain, EDTA and pepstatin, was used in the 
study and the procedures were performed at low temperature 
(4*C) (98).
Unlike PAP, PSA and PSP, the 7E11-C5 antigen is a 
cytoplasmic, insoluble glycoprotein complex, which 
complicates purification. Before classical techniques of
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biochemical purification could be applied, the antigen had 
to be converted into a soluble form. Detergents are most 
commonly employed for solubilizing membrane proteins. The 
detergents used in solubilization schemes can be divided 
into three classes: (1) non-ionic detergents, such as NP-40 
and glucoside; (2) zwitter-ionic detergents, such as CHAPS; 
and (3) ionic detergents, such as SDS. The choice of a 
detergent is determined by several factors, such as 
efficiency of solubilization, preservation of biological 
activity of the membrane protein and requirements for 
further purification procedures. The choice of detergent 
for membrane protein solubilization in immunoaffinity 
chromatography is restricted to those of a non-denaturing 
species because the denaturing reagents may damage the 
antibodies coupled to the gel matrices (56, 57). In the 
present study, the non-ionic detergent, NP-40, was found to 
be the most effective detergent for solubilizing the 7E11-C5 
antigen from extracts of LNCaP cells and LNCaP xenografts.
Organic solvent extraction procedures are also useful 
procedures for solubilizing membrane proteins containing 
proteolipids. Organic solvents, however, tend to cause 
protein denaturation and are not recommended if the 
biological activity of the membrane protein needs to be 
preserved. The compatibility between the solvents and 
further purification steps also needs to be considered. In 
the present study, a group of organic solvents was tested
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and the result showed that the antigen was sensitive to some 
of the solvents tested (Table X). However, considering that 
further purification by immunoaffinity chromatography, after 
solubilization, may be required, and not knowing the 
interaction of the organic solvents and the 7E11-C5 MAb 
coupled to the support matrix, organic solvents were not 
considered as good candidates for the solubilization step 
(58, 59).
Attempts to purify the solubilized antigen by molecular 
exclusion chromatography were unsuccessful. Gel filtration 
chromatography showed that all the 7E11-C5 antigen activity 
appeared in the void volume, using either Sephadex G-100, 
Sephadex G-200 or Sephacryl S-300 columns. Failure of the 
antigen to be separated by Sephacryl S-300 chromatography 
(fractionation range MW 10,000-1,500,000) suggested that 
after detergent solubilization, the size or shape of the 
antigen might be changed (size increased or globular shape 
changed to thread-like shape), causing ineffective 
separation of the antigen (60).
Some prostate-associated antigens such as PAP, PSA and 
PSP have been successfully purified by ion exchange 
chromatography (14, 26, 99). However, ion exchange 
chromatography was unsuccessful in separating the 7E11-C5 
antigen from contaminating proteins. The eluted 7E11-C5 
antigen was spread throughout the entire separation run. In 
this case, the eluted antigen had low antigen reactivity,
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suggesting a heterogeneous surface charge developed on the 
antigen after detergent solubilization.
After failure to effectively separate the 7E11-C5 
antigen by molecular exclusion chromatography and ion 
exchange chromatography, an attempt to purify the antigen by 
immunoaffinity chromatography was performed. Immunoaffinity 
chromatography is one of the most powerful techniques for 
the isolation of proteins. The preparation of solid-phase 
gel-linked antibodies involves both activation of the gel 
and coupling of antibody to the gel. This coupling should 
be highly efficient and the antibody must remain 
biologically active. In the present study, the gel matrix 
was cross-linked with amino groups of the 7E11-C5 MAb via 
the aldehyde reaction. The aldehyde group of the matrix (R- 
CHO) reacted with the amino group of the MAb (R'-+NH3 ), 
removing one molecule of water and forming reversible Schiff 
base (R-CH^NH-R'). Under reducing condition (NaBH3 CN), the 
Schiff base became a stable covalent linkage between the 
matrix and the MAb (R-CH-+NH2 ~R') (100). The advantages of 
this type of coupling are high coupling efficiency (> 80% 
for 7E11-C5 MAb) and stable linkage of immobilized MAb and 
matrix. The disadvantage of this coupling system, however, 
is that the matrix randomly binds to the amino group of the 
antibody, so that after the coupling, not all the MAb 
molecules are optimally oriented for antigen binding (62).
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Because antigenicity needs to be maintained, elution 
conditions should be as gentle as possible. An ideal 
elution buffer should yield a sharp peak with complete 
release of the antigen without damaging the antigen and the 
antibody. In the present study, an elution buffer 
consisting of 2 M MgCl2 was found to be the most effective 
buffer for eluting the 7E11-C5 antigen from the 
immunoaffinity column.
Western blot analysis indicated that the eluate from 
the immunoaffinity column consisted of two bands on SDS- 
PAGE, the 100-Kd band and a smaller (45-Kd) band. The 
smaller band was considered to represent possible 
degradation of the antigen. Although a single 7E11-C5 
reactive fraction was obtained by immunoaffinity 
chromatography, silver staining showed that there were 
several bands present on SDS-PAGE gel (Figure 12, B), 
suggesting that the antigen might not be totally pure.
HPLC molecular exclusion chromatography was used to 
further purify the antigen resulting in a single antigen 
reactive fraction, which was about 500-Kd in molecular 
weight. The 500-Kd molecular weight of the 7E11-C5 antigen 
under native condition open the possibility of that the 
antigen might consists of three monomers united by non- 
covalent bonds.
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The HPLC purified antigen was analyzed for N-terminal 
amino acid sequence and amino acid composition, but the 
results were inconclusive. Because the antigen was 
insoluble, the majority of the antigen became insoluble 
again during the purification procedures (removing the 
detergent), making it difficult to obtain an adequate amount 
of the antigen for sequencing. Efforts to overcome this 
problem will be required before amino acid analysis can be 
successful. One possible approach would be to "capture" the 
antigen on a nitrocellulose membrane. The membrane with the 
specific 7E11-C5 antigen active band(s) could then be 
directly analyzed for sequencing.
Biochemical and immunological characterization of the 
antigen was carried out with both crude and purified 7E11-C5 
antigen. Experiments using the purified molecule are 
recommended, because it is sometimes difficult to rule out 
the indirect effect from other contaminating components in 
the sample mixture (102). In this study, experiments using 
both antigen sources gave similar results. Some 
investigators have reported that chemical treatment might 
interfere with the ability of the antigen to adhere to a 96- 
well assay plate, therefore, Western blot analysis, rather 
than radioimmunoassay, was recommended (103). In the 
present study, experiments were carried out primarily using 
the modified radioimmunoassay procedures and selected 
samples also were analyzed by Western blot. Both
R eproduced  with perm ission of the copyright owner. Further reproduction prohibited without perm ission.
81
experiments yielded similar results, which confirmed the 
reliability of the radioimmunoassay procedures.
Periodate oxidation is a common procedure for 
structural analysis of glycoproteins and has been used to 
elucidate the participation of the carbohydrate moiety in 
the biological activity of glycoproteins (104). Periodate 
is a strong oxidizing reagent. A low concentration (< 10 
mM) can destroy the carbohydrate determinant without 
altering the protein or lipid component, while high 
concentrations can be destructive to peptide chains (65,
105, 106). The present study showed that the 7E11-C5 
antigen was sensitive to periodate treatment (Table V and 
Figure 14, lane J). The antigen was also sensitive to 
protease treatments, indicating that the 7E11-C5 antigen was 
a glycoprotein and that both carbohydrate and peptide were 
required for its antigenicity.
Enzymatic deglycosylation is also commonly used to 
study the specific sugar residue involvement in the 
glycoprotein molecule. Glycosidases specifically hydrolyze 
carbohydrates from glycopeptides or glycoproteins and 
release the free sugar residue. Such treatment of the 7E11- 
C5 (Table VII and Figure 15) showed that the 7E11-C5 antigen 
was sensitive only to beta-galactosidase. Galactosidase 
catalyzes the release of galactose residue from galactose 
conjugates, thereby suggesting that galactose is a major 
component of the 7E11-C5 antigenic determinant.
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Lectins are proteins or glycoproteins derived primarily 
from plants which can bind to specific carbohydrate groups 
on cells. A lectin competition assay was used to determine 
which carbohydrate(s) were involved in the 7E11-C5 antigenic 
determinant. The result of this experiment (Table VIII) 
showed that only the galactose-binding lectins (MPA and PNA) 
and N-acetyl-D-galactosamine-binding lectins (DBA and SBA) 
were able to block the binding of MAb 7E11-C5 to its target 
antigen, suggesting that both galactose and galNAc were 
involved in the 7E11-C5 antigenic determinant.
Carbohydrate competitive binding experiments showed 
that free carbohydrates or carbohydrate conjugates, 
including galactose and galNAc, were unable to block the 
antigen-binding site of the 7E11-C5 MAb. These results 
suggested that the size of the blocking carbohydrate 
molecules were not large enough to efficiently occupy the 
binding site, even though some larger aminosugars were 
tested (Table IX), or that the 7E11-C5 MAb had much higher 
affinity for the intact target antigen (a glycoprotein 
complex) than the sugar residue alone.
Metabolic labeling experiments suggest that 35s- 
methionine was not metabolically incorporate into proteins 
in cultured LNCaP cells. This might occur if the percentage 
of methionine in the 7E11-C5 molecule was low. This is 
substantiated by tentative results of the amino acid
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composition analysis which showed that only 0.6% methionine 
was present in the 7E11-C5 antigen (data from the Protein 
and Nucleic Acid Sequence Center at the University of 
Virginia). Another possible reason for the low 
incorporation of 35S-methionine might be due to the low 
metabolic rate of cultured LNCaP cells (doubling time is 72 
hours in vitro) (44).
Horoszewicz et al. reported that the 7E11-C5 antigen 
was shed in the serum of patients with CaP (43). In the 
present study, Western blot analysis and 7E11-C5 MAb 
inhibition assays were used in an attempt to detect the 
7E11-C5 antigen in serum. A total of 48 serum samples from 
normal male, BPH and all grades of CaP were analyzed by 
Western blot and the results did not confirm the presence of 
the 7E11-C5 antigen in serum samples, even those from CaP 
patients with advanced disease. Although there were some 
high molecular weight bands in the serum samples blot 
(Figure 17), the result from an isotype-matched negative 
antibody control indicated that those bands were nonspecific 
(Figure 18, B). There are approximately 75 ftg of protein 
per microliter in normal adult serum (107) and the 
sensitivity of Western blot analysis was reported to be 1 ng 
protein/band (77). In the present study, 4 jtl serum (about 
300 fig serum protein) were added to each lane of SDS-PAGE 
gel. If the 7E11-C5 antigen does exist in serum samples, 
the concentration must be extremely low.
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Horoszewicz et al. tested serum samples using an 
inhibition ELISA with LNCaP cells as the target antigen and 
reported that the 7E11-C5 antigen was shed primarily in sera 
from advanced stage CaP patients. In the present study, a 
modified inhibition radioimmunoassay using immunoaffinity 
purified antigen was used to test for the presence of 
antigen in serum, but again, the results could not confirm 
the previous report. In the present study the percent 
inhibition was high (52%-65%) regardless of the type of 
serum analyzed and there was no discrimination among the 
groups (Table XII). Normal female serum samples also showed 
similar positive results. In order to increase the 
specificity of the result, a direct inhibition assay, 
instead of a indirect inhibition assay, was used to measure 
the serum samples. The results from the two assays were 
similar (Table XIII). Considering the negative results 
obtained by Western blot, these high inhibition results 
suggest that molecules, other than the 7E11-C5 antigen, 
might have nonspecifically blocked the binding of the 7E11- 
C5 MAb.
Because the sensitivity of the inhibition assay used in 
the present study was limited (108, 109), failure to 
identify the 7E11-C5 antigen in the serum samples does not 
necessarily mean that there is no clinical significance for 
this prostate tumor-associated marker. A more sensitive 
double-determinant immunoassay may be required to accurately
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measure the 7E11-C5 antigen levels in serum and other body 
fluids. Development of a sensitive assay may also require 
the use of high affinity MAbs to at least two different 
epitopes on the 7E11-C5 antigen.
This study has provided important information regarding 
the biochemical and immunochemical nature of the target 
antigen recognized by MAb 7E11-C5. The inability to obtain 
adequate yields of purified antigen suggests that the 7E11- 
C5 antigen is tightly bound to cellular components highly 
resistant to standard solubilization procedures. The data 
also suggest that the antigen is unstable in a high salt 
environment. Because of the insoluble and unstable nature 
of the 7E11-C5 antigen and the low antigen yield obtained 
from cultured LNCaP cells and LNCaP xenograft, alternative 
approaches will be necessary to obtain adequate quantities 
of pure antigen needed for amino acid sequence analysis and 
the subsequent preparation of synthetic peptides or to 
isolate the cDNA clone and produce recombinant 7E11-C5 
antigens. These forms of the antigen could then be used for 
more definitive biochemical characterization of the 7E11-C5 
antigen, to prepare second generation antibodies for epitope 
characterization, and to develop a sensitive 2-site 
radioimmunoassay.
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